Catalyst
Slingshot members are tracking this event:
CytRx (CYTR) Announces Interim Phase 1b/2 Data Evaluating Aldoxorubicin in Patients with Advanced Sarcomas at the 2016 Annual Meeting of the Connective Tissue Oncology Society
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CYTR |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 11, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Interim Results, Phase 1b/2, Aldoxorubicin, Advanced Sarcomas, Ifosamide, Connective Tissue Oncology Society
